NCT06157892 2026-03-17
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
Clinical Trials
25 trialsNCT05132582 2026-03-16
HER2CLIMB-05
Seagen Inc.
Phase 3 Active not recruiting
NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05382364 2026-03-12
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Pfizer
Phase 1 Active not recruiting
NCT07413939 2026-03-10
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
NCT06016387 2026-02-23
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT06686394 2026-02-13
MK-1022-009
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05458674 2026-01-12
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT04721977 2026-01-09
MK-7119-001
Pfizer
Phase 2 Active not recruiting
NCT06961331 2026-01-09
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Pfizer
Completed
NCT03975647 2025-12-10
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT05253911 2025-12-04
TRACE
iOMEDICO AG
Completed
NCT05041842 2025-11-17
InTTercePT
UNICANCER
Phase 2 Active not recruiting
NCT04539938 2025-09-30
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT06239467 2025-09-09
PIKture-01
OnKure, Inc.
Phase 1 Recruiting
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT06439693 2025-06-26
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05868226 2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1 Recruiting
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting